SCHEMBL13137136

SCHEMBL13137136

Clc1cc(-c2ccc3[nH]cnc3c2)ccc1CNCC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
QPCT Q16769 2/20 0.38
CHEK1 O14757 1/20 0.37
CXCR4 P61073 3/20 0.37
EPHX1 P07099 1/20 0.36
SNCA P37840 1/20 0.36
HTR5A P47898 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
GSK3A P49840 1/20 0.36
ERN1 O75460 1/20 0.36
ROCK2 O75116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3050751 0.99 MEN1 (0.40) MEN1TP53CYP3A4CYP2D6CYP2C9
SCHEMBL13137141 0.90 BCHE (0.37) LMNAQPCTCHEK1EPHX1HTR5A
Hydrochloric Acid SCHEMBL3164169 0.89 BCHE (0.36) LMNAQPCTCHEK1EPHX1HTR5A
SCHEMBL13137097 0.87 HDAC3 (0.45) MEN1KMT2AQPCTEPHX1SNCA
SCHEMBL13137124 0.87 PIK3CA (0.36) MEN1KMT2AQPCTEPHX1SNCA
Hydrochloric Acid SCHEMBL3037830 0.86 HDAC3 (0.44) MEN1KMT2AQPCTEPHX1SNCA
Hydrochloric Acid SCHEMBL3043817 0.86 PIK3CA (0.36) MEN1KMT2AQPCTEPHX1SNCA
SCHEMBL13137143 0.84 CDK1 (0.39) QPCTEPHX1PIK3CAMTORGSK3A
SCHEMBL13137137 0.83 GCK (0.37) MEN1KMT2ALMNAQPCTCHEK1
SCHEMBL13137163 0.82 PRMT5 (0.44) QPCTSNCAPIK3CAMTORGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 MEN1 4829/4885TP53 4863/4885CYP3A4 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.